{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:49:38Z","timestamp":1779911378207,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10557-023-07494-5","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T07:02:26Z","timestamp":1691737346000},"page":"63-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study from 2019 to 2020 in China"],"prefix":"10.1007","volume":"39","author":[{"given":"Ke","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-0359","authenticated-orcid":false,"given":"Wu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaineng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"2","key":"7494_CR1","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.jinf.2020.04.021","volume":"81","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16\u201325.","journal-title":"J Infect"},{"issue":"3","key":"7494_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/jmv.26424","volume":"93","author":"J Li","year":"2021","unstructured":"Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449\u201358.","journal-title":"J Med Virol"},{"issue":"1","key":"7494_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41591-022-02158-7","volume":"29","author":"CE Dale","year":"2023","unstructured":"Dale CE, Takhar R, Carragher R, et al. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management. Nat Med. 2023;29(1):219\u201325.","journal-title":"Nat Med"},{"issue":"6","key":"7494_CR4","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13\u2013e115.","journal-title":"Hypertension"},{"issue":"18","key":"7494_CR5","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u2013e1032.","journal-title":"Circulation"},{"issue":"12","key":"7494_CR6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671\u201381.","journal-title":"Circ Res"},{"issue":"6","key":"7494_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ehjcvp\/pvaa056","volume":"6","author":"F Cannata","year":"2020","unstructured":"Cannata F, Chiarito M, Reimers B, et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):412\u20134.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"7494_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.120.16314","volume":"77","author":"L Semenzato","year":"2021","unstructured":"Semenzato L, Botton J, Drouin J, et al. Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients. Hypertension. 2021;77(3):833\u201342.","journal-title":"Hypertension"},{"issue":"2","key":"7494_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u201380.e8.","journal-title":"Cell"},{"issue":"2","key":"7494_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40292-022-00506-9","volume":"29","author":"G Gallo","year":"2022","unstructured":"Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Press Cardiovasc Prev. 2022;29(2):115\u201323.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"6","key":"7494_CR11","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","volume":"75","author":"AHJ Danser","year":"2020","unstructured":"Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75(6):1382\u20135.","journal-title":"Hypertension"},{"issue":"3","key":"7494_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.vph.2005.01.011","volume":"42","author":"JA Borland","year":"2005","unstructured":"Borland JA, Kelsall C, Yacoub MH, Chester AH. Expression, localisation and function of ACE and chymase in normal and atherosclerotic human coronary arteries. Vascul Pharmacol. 2005;42(3):99\u2013108.","journal-title":"Vascul Pharmacol"},{"issue":"23","key":"7494_CR13","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/092986711796642562","volume":"18","author":"A Kaparianos","year":"2011","unstructured":"Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18(23):3506\u201315.","journal-title":"Curr Med Chem"},{"key":"7494_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","volume":"40","author":"WSD Tan","year":"2018","unstructured":"Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9\u201317.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"7494_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40292-020-00401-1","volume":"27","author":"M Volpe","year":"2020","unstructured":"Volpe M, Battistoni A, Bellotti P, et al. Recommendations for cardiovascular prevention during the Sars-Cov-2 pandemic: an executive document by the Board of the Italian Society of Cardiovascular Prevention. High Blood Press Cardiovasc Prev. 2020;27(5):373\u20137.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"7494_CR16","doi-asserted-by":"crossref","unstructured":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J. 2022;43(11):1059\u2013103.","DOI":"10.1093\/eurheartj\/ehab866"},{"issue":"10","key":"7494_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345\u201355.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"7494_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/cid\/ciab493","volume":"74","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Luo W, Li Q, et al. Risk Factors for Death Among the First 80 543 Coronavirus Disease 2019 (COVID-19) Cases in China: relationships between age, underlying disease, case severity, and region. Clin Infect Dis. 2022;74(4):630\u20138.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"7494_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(22)00126-6","volume":"10","author":"L Huang","year":"2022","unstructured":"Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respirat Med. 2022;10(9):863\u201376.","journal-title":"Lancet Respirat Med"},{"key":"7494_CR20","doi-asserted-by":"publisher","first-page":"101668","DOI":"10.1016\/j.eclinm.2022.101668","volume":"54","author":"H Zhang","year":"2022","unstructured":"Zhang H, Li X, Huang L, et al. Lung-function trajectories in COVID-19 survivors after discharge: a two-year longitudinal cohort study. EClinicalMedicine. 2022;54:101668.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"7494_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.120.15464","volume":"76","author":"M Son","year":"2020","unstructured":"Son M, Seo J, Yang S. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea. Hypertension. 2020;76(3):742\u20139.","journal-title":"Hypertension"},{"issue":"4","key":"7494_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/HJH.0000000000002784","volume":"39","author":"C Bavishi","year":"2021","unstructured":"Bavishi C, Whelton PK, Mancia G, Corrao G, Messerli FH. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens. 2021;39(4):784\u201394.","journal-title":"J Hypertens"},{"issue":"9","key":"7494_CR23","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1020\u20136.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"7494_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1291\/hypres.31.553","volume":"31","author":"M Igase","year":"2008","unstructured":"Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res. 2008;31(3):553\u20139.","journal-title":"Hypertens Res"},{"issue":"1","key":"7494_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13054-020-03120-0","volume":"24","author":"W Ni","year":"2020","unstructured":"Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.","journal-title":"Crit Care"},{"issue":"3","key":"7494_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaci.2022.06.020","volume":"150","author":"L Kundura","year":"2022","unstructured":"Kundura L, Gimenez S, Cezar R, et al. Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19. J Allergy Clin Immunol. 2022;150(3):594\u2013603.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"7047","key":"7494_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112\u20136.","journal-title":"Nature"},{"key":"7494_CR28","doi-asserted-by":"publisher","unstructured":"Khalangot M, Sheichenko N, Gurianov V, Zakharchenko T, Kravchenko V, Tronko M. RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives. Front Endocrinol. 2023;14:1077959. https:\/\/doi.org\/10.3389\/fendo.2023.1077959","DOI":"10.3389\/fendo.2023.1077959"},{"issue":"10238","key":"7494_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","volume":"395","author":"FJ de Abajo","year":"2020","unstructured":"de Abajo FJ, Rodr\u00edguez-Mart\u00edn S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705\u201314.","journal-title":"Lancet"},{"issue":"23","key":"7494_CR30","doi-asserted-by":"publisher","first-page":"11031","DOI":"10.1111\/jcmm.17051","volume":"25","author":"HJ Zhao","year":"2021","unstructured":"Zhao HJ, Li Y, Wang DY, Yuan HT. ARB might be superior to ACEI for treatment of hypertensive COVID-19 patients. J Cell Mol Med. 2021;25(23):11031\u20134.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"7494_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros ESPGM, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. Jama. 2021;325(3):254\u201364.","journal-title":"Jama"},{"issue":"3","key":"7494_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14779072.2023.2184351","volume":"21","author":"JA Paguio","year":"2023","unstructured":"Paguio JA, Casipit BA, John TA, Balu A, Lo KB. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials. Expert Rev Cardiovasc Ther. 2023;21(3):219\u201326.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"7494_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/ehjcvp\/pvaa062","volume":"7","author":"S Liabeuf","year":"2021","unstructured":"Liabeuf S, Moragny J, Bennis Y, et al. Association between renin-angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):426\u201334.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"7494_CR34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1177\/147323000803600529","volume":"36","author":"G Uehara","year":"2008","unstructured":"Uehara G, Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI). J Int Med Res. 2008;36(5):1094\u2013102.","journal-title":"J Int Med Res"},{"issue":"10","key":"7494_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1253\/circrep.CR-20-0076","volume":"2","author":"T Nakajima","year":"2020","unstructured":"Nakajima T, Oh A, Saita S, et al. Comparative effectiveness of angiotensin II receptor blockers in patients with hypertension in Japan- systematic review and network meta-analysis. Circ Rep. 2020;2(10):576\u201386.","journal-title":"Circ Rep"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07494-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07494-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07494-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:18:32Z","timestamp":1738815512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07494-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7494"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07494-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2930798\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"23 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Research Ethics Committee of Tongji Medical College (no. TJ-IRB20210138).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare that this manuscript is being submitted for consideration for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}